Bone specialist Osteopore (ASX:OSX) has signed a Memorandum of Understanding (MOU) with China-based medical device innovation accelerator InnoVentures to commercialise Osteopore’s orthopaedic products in China. — Read more

Osteopore (OSX) and CellHeal have signed a binding term sheet to collaborate with a view to commercialising the use of Osteopore’s regenerative implant technology in China, Hong Kong, Macau, and Taiwan. — Read more

Osteopore’s bioresorbable mesh product, Osteomesh®, has received reimbursement approval from Discovery Health Medical Scheme (DHMS). Following its partnership with South African distributor Chronos Medical (Pty) Ltd, Osteopore is now aiming to incorporate more of its products into the DHMS reimbursement scheme, following regulatory approval. — Read more

With an initial three-year term, Majeton will immediately begin engaging with doctors and hospitals, both government and private. Osteopore aims to continue expanding its network to enable greater accessibility to a wider range of products targeting the Singapore dental and oral maxillofacial market. — Read more

Osteopore (ASX: OSX) signs two initial agreements with Accelerate Technologies Pte Ltd (A*STAR’s technology transfer arm) to license innovative bioactive technology designed to accelerate bone and tissue regeneration, for Osteopore’s incorporation into implants. — Read more

Osteopore (ASX: OSX) announces a strategic sub-distribution partnership with Kelyniam through its U.S. sales distribution partner, Bioplate Inc. to further penetrate the USD1.1 billion cranial implant market. — Read more

Osteopore shares digitalisation initiatives to increase efficiency. — Read more

In a major new development, bone healing company Osteopore (ASX:OSX) has been granted a patent in China for its ‘smart’ 3D biometric scaffolds. — Read more

Medical technology company Singular Health has partnered with innovative Australian scientific research agency CSIRO, on a project that is looking to develop an artificial intelligence-based tool to automatically design replacement “cranial implants” for 3D printing. The company has also entered into a collaboration with ASX-listed Osteopore to validate results of the project. — Read more

Regenerative implant innovators Osteopore and plastic and reconstructive surgeon Dr Michael Wagels have teamed up to conduct two ground-breaking human clinical trials. — Read more

After revolutionising reconstructive surgeries with regenerative implants that promote natural bone healing and tissue repair, Osteopore International is globalising its devices for broader use in dental, orthopaedic and spinal surgeries. — Read more

Medtech company Osteopore (ASX: OSX) will soon have it’s 3D-printed bone regeneration products in the view of major international medical markets through a new collaboration with one of the world’s largest medical companies. — Read more